

# Paramedic Initiated Lisinopril For Acute Stroke

<b>Submission date</b> 23/09/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 10/01/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 04/10/2013	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Gary Ford

**Contact details**  
Institute for Ageing and Health  
The Medical School  
Newcastle University  
Newcastle upon Tyne  
United Kingdom  
NE2 4HH

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**  
NCT01066572

**Secondary identifying numbers**  
NCTU5248

## Study information

**Scientific Title**

Paramedic Initiated Lisinopril For Acute Stroke: a pilot, double blinded, randomised, placebo controlled trial

**Acronym**

PIL-FAST

**Study objectives**

This study aims to assess the feasibility of a double blind parallel group randomised controlled trial of paramedic initiated treatment for patients with symptoms of recent stroke.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Newcastle and North Tyneside 2 Research Ethics Committee approved on the 19th August 2010 (ref: 10/H0907/33)

**Study design**

Double blind parallel group pilot randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Other

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please contact Gillian Watson [gillian.watson@ncl.ac.uk] to request a patient information sheet

**Health condition(s) or problem(s) studied**

Stroke with high blood pressure

**Interventions**

5 - 10 mg Lisinopril or matched placebo, once per day for seven days.

The total duration of follow up will be 7 days.

**Intervention Type**

Other

**Phase**

Not Applicable

## **Primary outcome measure**

Number of participants enrolled in the study per month

## **Secondary outcome measures**

1. The proportion of suspected acute stroke patients admitted to research sites during the trial duration who fulfilled the study eligibility criteria
2. The proportion of study eligible patients attended by a research-trained paramedic
3. The proportion of study eligible patients enrolled into the study by a research-trained paramedic
4. The proportion of study eligible patients approached about the research study but not enrolled, and the reasons for non-enrolment where possible
5. The proportion of study eligible patients not approached about the research study, and the reasons for non-approach where possible
6. The additional time spent on scene by research-trained paramedics to enrol a participant into the study
7. Paramedic compliance with study data collection
8. Hospital staff compliance with study medication administration and data collection
9. The proportion of study participants with confirmed stroke who complete seven days of study medication
10. Clinical outcome measures are blood pressure, neurological score, dependency score and renal function
11. Adverse Events in control and intervention groups during the study

Outcomes will be assessed at baseline, 3 and 7 days.

## **Overall study start date**

29/10/2010

## **Completion date**

28/10/2011

# **Eligibility**

## **Key inclusion criteria**

1. Adults greater than or equal to 40 years old
2. New unilateral arm weakness thought to be due to acute stroke within 3 hours of symptom onset
3. Hypertension as defined by systolic blood pressure (SBP) greater than 160 mmHg on two consecutive seated or lying readings taken 5 - 10 minutes apart
4. Conscious (eyes open spontaneously i.e. 'A' on Alert, Voice, Pain, Unresponsive [AVPU] scale)
5. Patient being transported to a PIL-FAST trial site (i.e. Royal Victoria Infirmary, North Tyneside General Hospital and Wansbeck General Hospital)
6. Verbal consent obtained from participant or next of kin

## **Participant type(s)**

Patient

## **Age group**

Adult

**Sex**

Both

**Target number of participants**

60

**Key exclusion criteria**

1. Aged less than 40 years
2. Females who are pregnant, lactating or at risk of pregnancy (i.e. who are not surgically sterile or at least 1 year post last menstrual period). Females less than 56 years of age consented by a relative will be excluded as menstrual history may be unknown.
3. Any presentation of suspected stroke without unilateral arm weakness
4. Cannot establish that stroke onset time (i.e. when patient was last seen well without symptoms) was within the last 3 hours
5. SBP less than 160 mmHg
6. Reduced level of consciousness (below 'A' on AVPU scale)
7. Patient not being transported to PIL-FAST trial site
8. Absence of participant or next of kin consent
9. Known to be taking ACE-inhibitor or Angiotensin II Receptor Blocker medication already
10. Known sensitivity to lisinopril or other ACE-inhibitor medication
11. Pulse greater than 120 beats per minute
12. Seizure activity in this illness episode (witnessed or history)
13. Hypoglycaemia (blood glucose less than 3.5 mmol/l)
14. Cannot walk independently prior to stroke (walking stick/frame is allowed)
15. Obvious understanding or memory problems when next of kin is absent
16. Significant head trauma or brain surgery in the last 3 months
17. Known renal failure
18. Known liver failure (or currently jaundiced)
19. Uncontrolled heart failure (breathlessness at rest)
20. Receiving palliative care for known malignancy
21. Currently enrolled in a clinical trial assessing a study drug

**Date of first enrolment**

29/10/2010

**Date of final enrolment**

28/10/2011

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Institute for Ageing and Health**  
Newcastle upon Tyne  
United Kingdom  
NE2 4HH

## **Sponsor information**

### **Organisation**

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

### **Sponsor details**

Joint Research Office  
Level 6 Leazes Wing  
Royal Victoria Infirmary  
Queen Victoria Road  
Newcastle upon Tyne  
England  
United Kingdom  
NE1 4LP

### **Sponsor type**

Hospital/treatment centre

### **Website**

<http://www.newcastle-hospitals.org.uk/>

### **ROR**

<https://ror.org/05p40t847>

## **Funder(s)**

### **Funder type**

Government

### **Funder Name**

National Institute for Health Research (NIHR) (UK) - Programme Grants for Applied Research  
(ref: RP-PG-0606-1241)

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	15/06/2011		Yes	No
<a href="#">Results article</a>	results	01/12/2014		Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No